QUIDELORTHO CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.26 USD | +0.81% |
|
-5.90% | -57.58% |
| 06-24 | RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating | MT |
| 06-05 | QuidelOrtho Seeks Inorganic Options | CI |
Presenter SpeechRuben Argueta (Executives)Good day, everyone, joining in through our webcast. ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
31.26
USD
Average target price
50
USD
Spread / Average Target
+59.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.58% | 2.09B | |
| -30.79% | 15.65B | |
| +19.25% | 1.88B | |
| -18.17% | 1.36B | |
| +25.65% | 1.28B | |
| +2.06% | 798M | |
| -33.66% | 762M | |
| -36.55% | 724M | |
| -30.00% | 586M | |
| -17.85% | 268M |
- Stock Market
- Equities
- QDEL Stock
- News QuidelOrtho Corporation
- Transcript : Quidel Corporation - Analyst/Investor Day
